
Fredrikson attorney Jamie Snelson [Photo courtesy of Fredrikson]
In the fourth and final part of our interview with two lawyers who work with medical device OEMs, their outsourcing partners and private equity firms on mergers and acquisitions (M&A), we discuss what their clients are looking for and how their shopping habits have changed.
Jamie Snelson and Carl Numrich are shareholders at Minneapolis-based law firm Fredrikson, which represents private equity platform sponsors including KKR (which just bought CDMO Integer for $5.7 billion), Bain Capital and Morgan Stanley.
Snelson works with medtech OEMs and was previously in-house legal counsel for Medtronic. He’s helped the world’s largest medical device company buy public companies and stock and assets of private businesses, along with dispositions, strategic investments and technology licensing deals.
Numrich represents PE firms and investment firms such as Audax, Arcline, Kolos Partners and Goldner Hawn.
Our first part of this interview covered the PE business model, the second part dug into what private equity means for medtech OEMs, suppliers and their employees, and the third part explored medtech M&A trends and the biggest dealbreaker.
The following has been lightly edited for clarity and space.
MDO: We cover innovative technologies like surgical robotics and pulsed-field ablation. What are the medtech applications that are most in-demand for your OEM clients who are looking to buy?
Snelson: “You still see a lot of innovation in cardiovascular and neuromodulation/neurostimulation. That’s been true for as long I’ve been doing this, 30 years in medical technology. We’ve got an aging population and continued complicating factors. Structural heart is one that has been of interest for a long time and is getting increasing interest as well. We see a lot of of the health IT activity — and this is broader than just Carl and me, but whether it’s back office systems or integration of artificial intelligence to anything you do, that’s true across all sectors — but healthcare and medical technology are susceptible to improvement in that regard. You mentioned robotics, which is impacting healthcare in a big way across every kind of surgical indication and activity that you see, and our clients are certainly involved there. But you don’t have to be extremely high tech to benefit from this M&A market. You can make very low-tech components and supplies, and if you do that well and with discipline, you’re going to be a really good acquisition target for the right buyer. Diabetes and metabolic disease technology has also been a need, and will an increasing need that we see. In vitro diagnostics on the pharma side, you see a lot of cancer applications and and technologies that are important. Anything that makes what would otherwise be invasive surgery less traumatic to the body is going to attract attention. Those are just a few things that we see a lot of activity in.”

Fredrikson attorney Carl Numrich [Photo courtesy of Fredrikson]
The 2026 Medtech Big 100: The world’s largest medical device companies ranked by revenue, employment and R&D spending
You’ve worked with Medtronic on a lot of M&A work. What’s changing about what the major medtech OEMs are looking for when they’re out shopping?
Snelson: “The dynamics in the market over the past five years have been somewhat volatile for anyone that touches the healthcare sectors writ large, but certainly our strategic clients have felt different pressures and greater uncertainty. There’s been regulatory scrutiny that has been volatile over the past several years, but I think our strategic clients — larger, even private-equity-backed sponsors — are feeling bullish about getting into this sector of medical technology and health IT and they see a lot of opportunity in it. It’s a very durable sector, plus the aging population and a lot of the dynamics that I’m sure your readership follows, and there’s still a lot of upside in medical technology that our clients in that sector see.”
Are buyers more risk-averse than before, and is there a difference in appetite for risk between the medtech strategics and PE buyers and how young of a company they’re willing to swallow before getting through regulators?
Snelson: “That’s a key difference between private equity and traditional medical technology. The medical technology businesses that we have worked with are often able to absorb a technology pre-revenue — while it’s still on the regulatory path — and use their resources to push that technology through to commercialization. Private equity is a little bit less tolerant of technologies that are still on the regulatory path that haven’t proven themselves in the commercial market.”
Numrich: “In other industry sectors in private equity, bigger is always better and scale is always king. In the healthcare deals that we’re seeing in the private equity space, it’s not just scale but smart scale that matters. And when you look at many funds — there are exceptions in the PE ecosystem where you have healthcare-specific funds — but many funds just don’t have the operational know-how to get a target through regulatory approvals and the like. So looking for targets that are mature enough with clean and sophisticated or at least built-out quality systems and compliance schemes is important for for many funds. They just don’t have the appetite or the the know-how or or frankly sometimes the time in the fund lifecycle to get through regulatory and be able to scale in the way that they need to eventually exit.”
Related: How device innovators can make the most of FDA’s TAP accelerator


